Rossanna C. Pezo
YOU?
Author Swipe
View article: Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study
Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study Open
Background/Objectives: Patients with breast cancer who do not achieve a complete response to neoadjuvant chemotherapy (NAC) may benefit from intensified adjuvant systemic therapy. However, such treatment escalation is typically delayed unt…
View article: Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results
Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results Open
Triple-negative breast cancer (TNBC) patients who have residual tumor at surgery (non-pathological complete response or non-pCR) after neoadjuvant chemotherapy (NAC) have a poor prognosis. In these cases, adjuvant chemotherapy with capecit…
View article: Role of Circulating Tumor DNA in Adapting Immunotherapy Approaches in Breast Cancer
Role of Circulating Tumor DNA in Adapting Immunotherapy Approaches in Breast Cancer Open
Immunotherapy has a defined role in the treatment of both early- and late-stage triple-negative breast cancer (TNBC) and is under active exploration in human epidermal receptor 2-positive as well as high-risk hormone-receptor-positive subt…
View article: Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy Open
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved survival in many advanced cancers including advanced melanoma, renal cell, urothelial, and no…
View article: Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review Open
Background Clinical trial reports often emphasize efficacy over harms, leading to misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed reporting of methods and results is especially important in …
View article: Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities Open
Immune checkpoint inhibitors (ICIs) have transformed the treatment of patients with advanced cancers. However, the majority of patients do not respond or develop early progressive disease. A substantial number also develop immune-mediated …